Archive for the ‘LPBI Group Founder – Aviva Lev-Ari’ Category

Testimonial on the English to Spanish Translation JOINT Project that yielded the “BioMed e-Series Spanish-language Edition” on Amazon.com

Interviewer: Verónica Oliver


Interviewee: Aviva Lev-Ari, PhD, RN, Founder, LPBI Group




[Edited version]

“A miracle that came true”. This is how Aviva Lev-Ari, PhD, RN founder of LPBI Group’s described what she and her venture had accomplished by partnering with Montero for a “monumental” #Medicine and #LifeSciences translation project. It was “monumental” because it involved 18 books in medicine 😊.

Dr. Lev-Ari is the editor-in-chief behind the Medicine and Life Sciences Scientific Journal, PharmaceuticalIntelligence.com  An open access scientific journal that has over 2.2 million views by over 1.4 million visitors. Over 6,170 scientific articles and over 740 categories of research in its ontology.

Between June 2013 and February 2021, LPBI Group’s team published eighteen 𝗲𝗹𝗲𝗰𝘁𝗿𝗼𝗻𝗶𝗰 medical 𝗯𝗼𝗼𝗸𝘀 covering five medical specialties:

These e-books, including 𝟮,𝟳𝟮𝟴 scientific 𝗮𝗿𝘁𝗶𝗰𝗹𝗲𝘀 curated and authored 𝗯𝘆 𝗯𝗶𝗼𝗺𝗲𝗱𝗶𝗰𝗮𝗹 experts and medical 𝗽𝗿𝗼𝗳𝗲𝘀𝘀𝗶𝗼𝗻𝗮𝗹𝘀 pursuing the quest to make the latest research available to healthcare professionals and accessible to the Global community of biological scientists, practicing physicians and medical students.

Now, 𝘄𝗵𝘆 𝗹𝗶𝗺𝗶𝘁 𝘁𝗵𝗲𝗶𝗿 𝗮𝗰𝗰𝗲𝘀𝘀 𝗼𝗻𝗹𝘆 𝘁𝗼 𝗮𝗻 𝗘𝗻𝗴𝗹𝗶𝘀𝗵-𝘀𝗽𝗲𝗮𝗸𝗶𝗻𝗴 𝗮𝘂𝗱𝗶𝗲𝗻𝗰𝗲?

With 471,000 million speakers in 22 countries, the Spanish language was the most relevant language to publish a new edition.

So, it was time to find the right #LanguageServiceProvider. Dr. Lev-Ari first contacted:

1️⃣ A company that couldn’t handle the project due to its size.

2️⃣ Another provider whose quote they couldn’t accept.

This led LPBI to adjust the scope of work and set certain boundaries, such as the budget for the project and making the decision that the project will focus on translation of the cover page of 18 e-books and the electronic Table of Contents (eTOCs) of these e-Books.

And then Aviva came across Fritz Handtke and Montero on LinkedIn. We held a couple of meetings to:

🤝 Define the scope of the project.

🤝 Create a methodology we could repeat 18 times.

🤝 Show LPBI how we work, including the software used to avoid counting (and charging for) repeated words.

🤝 Introduce our experts in the medical field to them.

Aviva’s acceptance of our quote marked the beginning of a very smooth collaboration.

It took us less than five months, involving three #MedicalTranslators, to deliver the eTOCs in Spanish (for 𝟭𝟵 𝗯𝗼𝗼𝗸𝘀 divided into five series).

The result of this project was “a new genre of the original #biomed e-Series.” In each volume of the Spanish-language Edition: PART A is Spanish audios, PART B is Bilingual texts, and PART C is editorials in English.

When we asked Dr. Lev-Ari about her experience with Montero, she highlighted the following points:

1️⃣ “At all times, there was 𝗼𝗻𝗲 𝘀𝗶𝗻𝗴𝗹𝗲 𝗽𝗲𝗿𝘀𝗼𝗻 𝗮𝘀𝘀𝗶𝗴𝗻𝗲𝗱 𝘁𝗼 𝗺𝘆 𝗽𝗿𝗼𝗷𝗲𝗰𝘁.”

2️⃣ “One of the editors of the series A in cardiovascular is a Spanish-speaking cardiologist. He reviewed 2 books and confirmed the 𝘁𝗿𝗮𝗻𝘀𝗹𝗮𝘁𝗶𝗼𝗻 𝗮𝗰𝗰𝘂𝗿𝗮𝗰𝘆.”

3️⃣ “Their 𝗿𝗲𝘀𝗽𝗼𝗻𝘀𝗲 𝘁𝗶𝗺𝗲 was most favorable. After submitting a file, I got the translation within a week. For any questions, I’d receive a timely response.”

Imagine how thrilled we were to hear her say:

“Congratulations to Montero because they delivered a very monumental project. Without our collaboration, that would have most likely not have happened.”

Thanks to Aviva and LPBI Group for your trust in Montero!

You can find all 37 books here





“I needed a partner that I could rely on for quality, interactivity, timing and budget. Montero was outstanding on all these counts.”


Read Full Post »

Tweets at #WMIF2022 by @pharma_BI & @AVIVA1950 and All Retweets of these Tweets – 2022 World Medical Innovation Forum, GENE & CELL THERAPY • MAY 2–4, 2022 • BOSTON

Real Time coverage: Aviva Lev-Ari, PhD, RN

Updated on 5/9/2022

Lessons on the Frontier of Gene & Cell Therapy – The Disruptive Dozen 12 #GCT Breakthroughs that are revolutionizing Healthcare

Reporter: Aviva Lev-Ari, PhD, RN


2022 World Medical Innovation Forum, GENE & CELL THERAPY • MAY 2–4, 2022 • BOSTON • IN-PERSON


Liked Tweets by Conference Organizers

UPDATED on 5/11/2022


by Mass General Brigham Innovation


Aviva Lev-Ari

#genetherapy for tuberous sclerosis complex tested on mice found effective in combination with drug in use longer survival to 150 days 10,000 cases in US per year, gene therapy most promising for this gene malfunction #WMIF2022

Quote Tweet
Mass General Brigham Innovation
Take a First Look at Dr. Vijaya Ramesh’s research demonstrating preclinical efficacy of an #AAV-based #genetherapy for tuberous sclerosis complex, setting the stage for future IND-enabling studies & clinical translation. #WMIF2022 @MGH_RI @MGHNeurology youtube.com/watch?v=-I_XiS

Top 6 #WMIF2022 #GCT #CARTTherapy #DisruptiveDozen @MGBInnovation @pharma_BI @AVIVA1950 1 Restoring sight by edit genes 2 A gene editing solution supply of donor organs 3 Cell therapies for blindness 4 RNA to treat brain cancer 5 #GCT for brain disorders 6 fighting viruses

liked 2 of your Tweets

7 to 12 #WMIF2022 @MGBInnovation #GCT #DisruptiveDozen @pharma_BI @AVIVA1950 7 Cell therapies restore gut motility 8 CAR-T at autoimmune diseases 9 Regrowing cells in the inner ear hearing loss 10 tech delivering gene therapies 11 target solid tumors 12 X-chromosome neurodegen


by Tracy Doyle

#KOL on #Cell therapies: #CAR-T cells and #stem-cell-based approaches is moderator for Cell Therapy Landscape: Marcela Maus, MD, PhD Director, Cellular #Immunotherapy Program, #Cancer Center, MGH Associate Professor, Medicine, HMS @MGBInnovation @pharma_BI @AVIVA1950 #WMIF2022

Global views #GCT Christine Fox, Novartis Gene Therapies C. Baum, MD, Berlin Institute of Health Nicholas Galakatos, PhD, Blackstone Luigi Naldini, MD, PhD Telethon Institute, Kendra Rose, PhD, Bayer #WMIF2022 @MGBInnovation @MassGenBrigham @pharma_BI @AVIVA1950

and 2 others liked your Tweet

#Chronic #Neuroinflammation #MS, #AD, #Parkinsons #GCT #genomics Ole Isacson, MD, PhD @McLean Colin Hill CEO, GNS Spyros P., MD, PhD Vigil, Ransohoff, MD, Abata & Third Rock, B. Stevens, PhD, Boston Children’s R. Tanzi, PhD @MGH #WMIF2022 @MGBInnovation @pharma_BI @AVIVA1950

liked 2 of your Tweets

#fundraising #GCT #startups Panelists: Shelley Chu, MD, PhD Partner, Lightspeed Stephen Knight, MD President, F-Prime Capital Adam Koppel, MD, PhD, Bain Capital Life Sciences Daniel Krizek Portfolio Manager, Citadel #WMIF2022 @MGBInnovation @MassGenBrigham @pharma_BI @AVIVA1950

Retweeted your Tweet

#fundraising #GCT #startups Panelists: Shelley Chu, MD, PhD Partner, Lightspeed Stephen Knight, MD President, F-Prime Capital Adam Koppel, MD, PhD, Bain Capital Life Sciences Daniel Krizek Portfolio Manager, Citadel #WMIF2022 @MGBInnovation @MassGenBrigham @pharma_BI @AVIVA1950

Jean-François Formela, MD, Partner @atlasventure on stage with profound #insights on the #interface and seam line between #Medical applications #investment in #health #innovations #WMIF2022 @MGBInnovation @MassGenBrigham @pharma_BI @AVIVA1950 #vision and #inspirations

Retweeted your Tweet

#1 #global #conference #CGT #WMIF2022 @MGBInnovation World Medical Innovation Forum #translation and #regenerative #medicine #gene #editing #gene #therapy @pharma_BI @AVIVA1950 Therapeutics Promise #CGT for #Cardiovascular #Diseases since 12/26/2015 lnkd.in/dwqM3K3


by Bob Coughlin


Aviva Lev-Ari

Quote Tweet
Mass General Brigham Innovation
Someone in the US is diagnosed with #Alzheimers roughly every 60 seconds. Dr. Stephen Haggarty @neuro_mgh shares a First Look at his work to prevent the accumulation of toxic proteins that cause age-dependent #neurodegeneration at #WMIF2022. worldmedicalinnovation.org/wp-content/upl

Aviva Lev-Ari

Breakthrough in ophthalmic drug delivery new #gel delivery system for eye diseases like #retinitis #pigmentosa #WMIF2022

Quote Tweet
Tracy Doyle
Michael Young, PhD, Schepens Eye Research Institute @MassEyeAndEar, shares preview of new gel delivery system for eye diseases like retinitis pigmentosa at FirstLook research updates @MGBInnovation #WMIF2022



Bob Coughlin


liked your Tweet

#1 #global #conference #CGT #WMIF2022 @MGBInnovation World Medical Innovation Forum #translation and #regenerative #medicine #gene #editing #gene #therapy @pharma_BI @AVIVA1950 Therapeutics Promise #CGT for #Cardiovascular #Diseases since 12/26/2015 lnkd.in/dwqM3K3


by Mass General Brigham Innovation


Aviva Lev-Ari

Breakthrough in ophthalmic drug delivery new #gel delivery system for eye diseases like #retinitis #pigmentosa #WMIF2022

Quote Tweet
Tracy Doyle
Michael Young, PhD, Schepens Eye Research Institute @MassEyeAndEar, shares preview of new gel delivery system for eye diseases like retinitis pigmentosa at FirstLook research updates @MGBInnovation #WMIF2022



Tweets at #WMIF2022 by

@pharma_BI & @AVIVA1950

Aviva Lev-Ari

Geoff Meacham, PhD BofA Securities w/Panelist: Robert Bradway CEO, Amgen strategies in #drug #design #development addressing #chronic aspects of #cancer and #cardiovascular #WMIF2022

Series A: Cardiovascular Diseases
Visit Amazon’s Series A: Cardiovascular Diseases Page and shop for all Series A: Cardiovascular Diseases books. Check out pictures, author information, and reviews of Series A: Cardiovascular Diseases

ReTweets of Tweets at #WMIF2022 by

@pharma_BI & @AVIVA1950



See at https://twitter.com/StephenJWillia2

Retweets at #WMIF2022 by

@pharma_BI & @AVIVA1950 and by others

Retweeting Tweets or Retweets by

@pharma_BI & @AVIVA1950

Mass General Brigham Innovation

#ICYMI – Yesterday, Dr. Robert Califf

, Commissioner Food and Drugs

, joined us at #WMIF2022 for a Fireside Chat. Watch the full session online NOW on the World Medical Innovation Forum YouTube channel.

2022 WMIF | 1:1 Fireside Chat: Robert Califf, MD, Commissioner Food…
1:1 Fireside Chat: Robert Califf, MD, Commissioner Food and Drugs, FDATazeen Ahmad, Managing Director, Global Research, BofA SecuritiesJ. Keith Joung, MD, Ph…

James Beck, PhD

Looking forward to joining panel on patient perspective on gene & cell therapies @ #WMIF2022. People with #Parkinsons may benefit greatly.

is doing a great job of quickly posting sessions YouTube channel for those who cannot attend.

World Medical Innovation Forum
The World Medical Innovation Forum is a global gathering of more than 1,200 senior health care leaders hosted by Mass General Brigham in the heart of Boston. It was established to respond to the…

Aviva Lev-Ari

Geoff Meacham, PhD BofA Securities w/Panelist: Robert Bradway CEO, Amgen strategies in #drug #design #development addressing #chronic aspects of #cancer and #cardiovascular #WMIF2022

Series A: Cardiovascular Diseases
Visit Amazon’s Series A: Cardiovascular Diseases Page and shop for all Series A: Cardiovascular Diseases books. Check out pictures, author information, and reviews of Series A: Cardiovascular Diseases

Mass General Brigham Innovation

Dr. Rosana Kapeller

will be shining a light on the #darkgenome in today’s Dr. Is In session “The Mysterious Dark Genome” at #WMIF2022. Join her and experts from





at 11:45 AM in the St. George room.

Erica Robinson

May is Brain Tumor Awareness Month. This is my brilliant neurosurgeon

who has been named the new Chief Medical Officer of

. Congratulations! I was blessed to get connected with you in 2010. #BTSM #BTAM

Quote Tweet
Mass General MDs
Congratulations to William Curry, MD, @WTCNeuroscience the new chief medical officer of #MassGeneral and the MGPO, effective 6/1. We know he will continue his work to improve the outcomes for patients and train the next generation of leaders. @MGHNeurosurg



Aviva Lev-Ari

#WMIF2022 #glioblastoma, the most common malignant brain tumor, and one of the most treatment-resistant and fatal human diseases

Read the full abstract here: worldmedicalinnovation.org/wp-content/upl

Quote Tweet
Mass General Brigham Innovation
Dr. Anna Krichevsky shares a First Look at her work developing #RNA-targeting therapies for #glioblastoma, the most common malignant brain tumor, and one of the most treatment-resistant and fatal human diseases. #WMIF2022 Read the full abstract here: worldmedicalinnovation.org/wp-content/upl



Aviva Lev-Ari

Quote Tweet
Bob Coughlin
Great way to start the week. @MGBInnovation World Medical Innovation Forum. 3 days of #CGT talks! #WMIF2022 @MassGenBrigham #worldclass #PatientDriven TY @ChrisMarkCOBURN and team for all you do for patients! @JLL #lifesciencebroker



Read Full Post »

We Celebrate TEN Years of Excellence, LPBI Group: 4/2012 – 4/2022

Author: Aviva Lev-Ari, PhD, RN, LPBI Group Founder

Updated on 1/19/2023

Five Bilingual BioMed e-Series – 37 volumes

Curator, Book Editor & Bilingual BioMed e-Series, Editor-in-Chief:

Aviva Lev-Ari, PhD, RN

  • English Edition:  18 volumes in 17 books, and
  • Spanish Edition (EDICIÓN EN ESPAÑOL): 19 volumes in 19 books


  • 1.0 LPBI: 4/2012 – 12/2022
  • 2.0 LPBI: 1/2021 – Present to 2025

See as well,

2022 Update from LPBI Group 

This article has five parts:

Part 1: Web Site Statistics

Part 2: 2.0 LPBI Group’s Four Missions: The Pipelines for 2021-2025

Part 3: Portfolio of IP Assets

Part 4: Certificates – One Year Academic Internships in six Disciplines

Part 5: Top 14 Articles by Views, All Time


For ten years, now, Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston, MA – flagship Journal had amassed +2.1 MM views


2022 Update from LPBI Group

Author & Curator: Aviva Lev-Ari, PhD, RN


The Founder has  8,148 followers  on LinkedIn.com


Analytics of e-Reputation


The Founder is the Editor-in-Chief for the Journal and for the BioMed e-Series – an eighteen volume series of electronic Books in Medicine


Page downloads on 4-6-2022

N = 147,069 (till end of Feb. 2022)

Equivalent to 74 Books

Abbreviated electronic Table of Contents (eTOCs) of each Volume in the EIGHTEEN-Volume BioMed e-Series


The Team that produced 18 books in Medicine


LPBI Group’s CSO, 2012-2017: Dr. Larry H. Bernstein, MD, FCAP


The Founder is a UC, Berkeley PhD’83 who had worked at Director Level for SRI Int’l, MITRE, PSC, McGraw Hill. Other employer organizations includes: Monitor Company (now Deloitte), Amdahl Corporation (now Fujitsu), PSC (now Dell Technologies).  Positions in Healthcare are described in this link: http://Scientific and Medical Affairs Chronological CV

Aviva Lev-Ari, PhD, RN

Director & Founder


Picture date: 2/6/2022

While you are reviewing LPBI Group’s Portfolio of IP assets


you will note that LPBI Group is venturing into Scientific NFT Marketplaces


We plan to MINT as NFTs several of LPBI Group’s IP Asset Classes, such as

  • Curations among our +6,100 Journal articles – IP Asset Class I
  • eTOCs – Electronic Table of Contents of our 18 Books – IP Asset Class II
  • Gallery of +6200 Biological Images embedded in our Journal articles – IP Asset Class V
  • E-Proceedings of +100 Medical and Biotech Conferences we had covered in Real Time, 2013 – 2022 – IP Asset Class III
  • Tweet Collections of the latest 40 Medical and Biotech Conferences we had covered in Real Time, 2013 – 2022 – IP Asset Class III


Tweet Collection of 2022 #EmTechDigital @MIT, March 29-30, 2022


Analytics for @AVIVA1950 Tweeting at #EmTechDigital


Review our Testimonials


Our PAST is here




Our FUTURE is here






Podcast of our Leaders are here


A stream of Ten INNOVATIONS in the Life of LPBI since

inception in 2012 to 2022

  1. 4/2012 – LPBI was the Launcher of a novel Scientific Curation Methodology for scientific findings in published primary research in the Global e-Scientific Publishing industry https://pharmaceuticalintelligence.com/
  2. As late as 2016, no big publisher, not even one, i.e., Elsevier, John Wiley had curation-based publications: Journals, Books, e-Proceedings or Gallery of thousands of Biological Images as an IP asset class
  3. At LPBI, Curation of scientific findings was performed in +6,000 articles with +2MM e-Views by Global e-Readers
  4. 6/2013 – LPBI was the Publisher of the 1st e-book in Medicine in Kindle Store on the Life Sciences & Medicine Shelf – Upload to this shelf by Amazon.com
  5. 2/2021 – Completion of the 18 volumes, BioMed e-Series in five Specialties in Medicine: each article in each volume is a curation-based publication.
  6. On Amazon.com on 7/2021 – LPBI’s e-books in Medicine enjoy +128,100 PAGE DOWNLOADS – the ONE and ONLY publisher in that range of page downloads. The record is the equivalent of 64 books at an average of 2,000 pages a volume !!!! LPBI smallest book is 1,000 pages and its biggest is +3,700 pages
  7. LPBI launched its Natural Language Processing (NLP) Practice in 1/2020 as Mission #1. NLP is one method of Machine Learning (ML). ML is a family of methods in Artificial Intelligence (AI) which is a field in the Computer Science Academic discipline since the early 60s.
  8. In 4/2021 Linguamatics/IQVIA performed NLP on LPBI’s 33 articles and 20 Biological Images. RESULTS:  +670 entity relations DISCOVERED by Linguamatics and unknown to Pharma and to Insurers, entity relations between:
  • Gene-Disease
  • Gene-Drug
  • Disease-Drug

These results were jointly presented to a Healthcare Insurer, SLC, UT on 7/13/2021, forthcoming meeting in 9/2021.

LPBI and BurstIQ are architecting NOW the first Natural Language Processing – Blockchain Information Technology infrastructure in existence, This statement is TRUE.

  • Updated on 7/28/2021:Fluree Flur.ee, the Web3 Data Platform Open source semantic graph database & LeadSemantics.com presented their solution for NLP and Blockchain on 7/28/2021. Erich G. was lured as Chief architect for LPBI’s Mission #2: NLP & Blockchain
  • Linguamatics, the leader in NLP did not hear of Blockchain and BurstIQ did not have a request for NLP – LPBI PUT THESE TWO TECHNOLOGIES AND PARTIES TOGETHER

See IMAGES SOURCE: BurstIQ image for LPBI


  • On 7/19/2021 – LPBI had launched LPBI India for Synthetic Biology Software for Drug Discovery targeting Galectins – Collaboration with Dr. Raphael Nir, President and CSO, SBH Sciences, Inc., Natick, MA
  • On 7/25/2021 – LPBI announced that it will have the NEWLY to be published BioMed e-Books As Mission #3:

o    Bi-Lingual electronic Table Of Contents (eTOCs), English & Spanish with Montero Language Services, Madrid as the Translator of eighteen Books’ Cover Pages and the 18 books electronic Table of Contents.

o    The Content promotion in the Spanish speaking Countries with GTO, Madrid as AD Agency.

o    NLPs results of Medical Text Analysis with domain knowledge expert Interpretations in Foreign Languages and in Audio: in Spanish and in other languages, forthcoming

o    Original English Book – Only Editorials (Preface, Introductions, Summaries and Epilogue) because the Bi-Lingual part has the eTOCs of the e-Book

o    This is a new genre and a new architecture of 18 MULTIMEDIA SCIENTIFIC e-Books with (a) NLP results of the Medical Text analysis with machine learning, (b) Expert Interpretation of the Visualization Results. Bi-Lingual Podcasts: (c) eTOCs and (d) Bi-Lingual Expert Interpretation in English and Spanish Text and audio Podcasts, and (e) Books’ Editorials in English Audio Podcast

Content promotion proposal by GTO, Madrid

See IMAGES SOURCE: Rendition by GTO, Madrid of BurstIQ Image, above

2.0 LPBI is a Very Unique Organization 

9. The Content Monetization effort includes the Price List for LPBI 1.0 digital products and of LPBI 2.0 – NLP Products

Under development

  • IP Valuation Model per IP asset class is needed to be compared with Master_Financials and to supplement it
  • Pricing Model and Product Mix Models for the digital products to be generated by the process of Text Analysis with NLP are using a Product Price List already developed.
  • The scenarios for a Probabilistic Product Mix for the B2B sector are work-in-progress. Scenarios of Product Mix for $500,000 B2B engagements with NLP scaling up with NLP Alliances. The Alliances are the Labor component and LPBI represent Materials (Content) as 25% of the contract price, on top of total, to be paid by the B2B customer as materials in use for the engagement.
  • B2C Customers on Blockchain will use the Price List for all Digital Products of LPBI 1.0 and LPBI 2.0 – Pay per Use

10. LPBI Group runs FIVE ACADEMIC INTERNSHIPS as Certificate Programs: a One Year long or a One Semester long: Volunteer base offering Verifiable Certificates, as described in https://pharmaceuticalintelligence.com/certificate-1-year/

Read Full Post »

Analytics for @AVIVA1950 Tweeting at #EmTechDigital

Reporter and Curator: Aviva Lev-Ari, PhD, RN



See also

Tweet Collection of 2022 EmTechDigital @MIT, March 29-30, 2022

Tweet Author: Aviva Lev-Ari, PhD, RN

Selective Tweet Retweets for The Technology Review: Aviva Lev-Ari, PhD, RN



Top Tweet earned 122 impressions

Prem Natarajan Vice President Alexa AI device and broadly decisions what stay on edge vs cloud physical obstacles to learn language less constrained Alexa5 more creative
 1  2

Top mention earned 7 engagements

Agrim Gupta, Stanford Vision Learning Lab, Stanford University Baldwin Effect genotypic modification phynotypic behavior GPT-OpenAI CLIP MetaMorph process transformer Encode Decode
 1  1
Engagement rate

Read Full Post »

Equity Sharing Calculation: A Scoring System for Author’s (a) Total Articles (single author) and (b) multiple authors (c) Total Articles Views (d) Author’s Proportion of own articles views in the Top 14 Journal articles by Views and (e) External Citations (f) Influencer on Twitter

Curators: Aviva Lev-Ari, PhD, RN and Stephen J. Williams, PhD

LPBI Group had developed a Scoring System for attribution of Equity Sharing in IP Asset Class I: Journal articles to Top Authors by number of articles published and by Views at all time for all articles published in the Journal

UPDATED on 10/12/2022 for 4/10/2019

(f) Influencer ranking at World Medical Innovation Forum ARTIFICIAL INTELLIGENCE in MEDICINE

Top 3 Ranked by Betweenness Centrality in Top 10 Influencers   Twitter Analytics by NodeXL for #WMIF19 by 

@PHSInnovation  at World Medical Innovation Forum ARTIFICIAL INTELLIGENCE, Boston, MA USA, Monday, April 8-10, 2019

‘s  Hashtags  – Twitter Analytics published for http://bit.ly/WMIF19 

  • [Top 10 by Mentions – @pharma_BI = 4 with 181 mentions]  

  • [Top 10 by Tweets @AVIVA1950 = 2 with 229 Tweets (N = 152 Direct messages)]


Recognition for LPBI Group’s IP Asset Class III: e-Proceedings and Tweet Collections



UPDATED on 5/24/2022

(e) External Citations

More details are found in



(a) Author’s Total Articles (single author) 

(b) Author’s multiple authors articles

(c) Author’s Total Articles Views 

(d) Author’s Proportion of own articles views in the Top 14 Journal articles by Views

(e) External Citations – See UPDATED on 5/24/2022, above


(f) Global Score across all the parameters

Read Full Post »

Analytics for e-Reputation based on LinkedIn 1st Degree Connections, +7,500 of LPBI Group’s Founder, 2012-2022: An Intangible Asset – Connections’ Position Seniority & Biotech / Pharma Focus

Author: Aviva Lev-Ari, PhD, RN, Founder of 1.0 LPBI, 2012-2020 & 2.0 LPBI, 2021-2025


Data Scientist, Research Assistant III: Tianzuo George Li

LPBI Group Logo

Picture date: 2/6/2022

Aviva Lev-Ari, PhD, RN

Founder of 1.0 LPBI, 2012-2020 & 2.0 LPBI, 2021-2025



We discussed the relations of e-Reputation as an Intangible Asset of the Firm in the following articles:

The Digital Age Gave Rise to New Definitions – New Benchmarks were born on the World Wide Web for the Intangible Asset of Firm’s Reputation: Pay a Premium for buying e-Reputation

Curator: Aviva Lev–Ari, PhD, RN

Curator: Aviva Lev-Ari, PhD, RN

Additional parameters of e-Reputation as an intangible asset for LPBI Group’s Founder and for LPBI Group as a Firm are analyzed in other articles, see the following List of Links:

UPDATED on 5/9/2022

Based on 2/13/2022 data download

LPBI Group’s Founder’s 1st Degree Connections on LinkedIn by

Sector Type and by Number of Connections in each Sector


Sector Type Number of Connections
Big Pharma 130
University 99
Academic Medical Center 53
CRO 46
Biotech 35
Cloud Computing 29
Genomics 24
Medical School 22
Medical Devices 18
Medical Equipment 18
Academic Medical Center – Israel 17
Big Pharma – Israel 15
Big Pharma – Japan 15
BioSciences 15
Cloud IT 15
Medical Research Institute 15
Institute of Technology 11
Biological Sciences Research Institute  Israel 10
Healthcare Insurance 10
Scientific Publisher 10
Biotech – Immunotherapy 9
Biotech – Israel 9
Government Agency – Drug Administration 8
Healthcare Insurance Company 8
Big Pharma – France 7
Institute of Technology – Israel 7
Medical Professional Association 7
Research Institute 7
HMO – Israel 6
Large Biotech 6
Media 6
Top Four Accounting 6
University – UK 6
Big Four Accounting 5
BioInstrumentation – Genomics 5
Medical Center 5
Technology Transfer Office – Israel 5
VC 5
Business/diplomacy – Israel 4
Federal Agency 4
Medical Research Institute/Foundation 4
University – Canada 4
Government Office – Israel 3
Top Tier Management Consultinf on IT 3
Top Tier Management Consulting 3
Univeristy – Israel 3
World Largest Thinktank 3
Big Pharma – Swiss 2
Big Pharma – US 2
BioMed Research Institute, ME Independent non-profit 2
BioTech PharmacoGenomics 2
Community Hospital 2
Government funded Basic Research 2
Government funded R&D 2
Government funded R&D – Israel 2
Management Consulting 2
Medical Center – Israel 2
Medical Devices – Israel 2
Medical Office 2
Medical Professional Accociation – Israel 2
Pharma – India 2
Professional Association 2
Professional Medical Society 2
Research Institute – Israel 2
Research Institute on Hightech – Israel 2
Top Four Accounting – Israel 2
Top Tier Management Counsulting – India 2
University – Australia 2
University – Israel 2
VC – Israel 2
3D Bioprinting – Dental 1
Academic Medical Center – Canada 1
Academic Medical Center – Spain 1
Academic Medical Center – Sweden 1
Academic Medical Center- Israel 1
Academic Medical School 1
AI 1
Big Pharma – Europe 1
Big Pharma – Poland 1
BioMed 1
BioMed AI 1
Biotech – Immunotherapy – Germany 1
Biotech & Gne Medicine –               USA & Canada 1
Biotech Consorsium 1
Business – Israel 1
Business Association NE & Israel 1
Community Medical Center 1
Economic Research Institute 1
Governement funded Research 1
Government Ministry of Health – Israel 1
Government Office – China 1
Government Office -Taiwan 1
Government Research Center 1
Healthcare R&D – India 1
HMO & Healthcare Insurance 1
Institute of Technology – India 1
Law Firm 1
Library – Israel 1
Life Science Institute – Japan 1
Medical Center – Canada 1
Medical Center – India 1
Medical Center (VA) 1
Medical Clinic 1
Medical Equipment – Israel 1
Medical Institute/Foundation 1
Medical Professional Society 1
Medical Research Center 1
Medical Research Institute – Academic Medical Center 1
Medical Research Institute – Canada 1
Medical Research Institute (VA) 1
Medical School – Brazil 1
Medical School – Bulgaria 1
Medical School – Canada 1
Medical School – Iran 1
Medical School – Spain 1
Medical School – Thailand 1
Medical Technology & Equipment 1
NGO – Healthcare 1
Pathology – AI 1
Pathology – AI – Israel 1
Pharma – France 1
Pharma manufacturer – Ireland 1
Pharma R&D – Not by Pharma 1
Pharmaceutical & Biotech MEDIA 1
Pharmaceutics – Switzerland 1
Professional Accociation – Denmark 1
Professional Medical Association 1
Research Center                    Independent Non-profit 1
Research Institute – Indonesia 1
Research Institute (Private) – Brazil 1
Research Institute at                  Academic Mmedical Center – Israel 1
Research Institute/Foundation 1
Scientific Publisher – Sweden 1
Top Four Accounting – South East Asia 1
Top Tier Medical Consulting 1
Univeristy – Israel – AFTAU 1
University –  Latvia 1
University –  Oman 1
University –  Romania 1
University – Denmark 1
University – Finland 1
University – Germany 1
University – Greece 1
University – Italy 1
University – Porto Rico 1
University Health Services 1
VC – High Tech & Healthcare – Israel 1
VC – Hightech and Biotech 1
VC Biotech 1
VC Medical Devices & Pharma – Israel 1



The presentation of this one parameter focus on two dimensions: 

  • Dimension #1: The Position Seniority of the Connections, and
  • Dimension #2: The industry concentration in Biotech / Pharma 

Summary and Conclusions:

Founder’s LinkedIn 1st Degree Connections, N = +7,500

The industries represented by multiple 1st Degree Connections of LPBI Group’s Founder are the following:

  • Biotech & Pharma: Teva Pharmaceuticals, Novartis, AstraZeneca, J&J, Philips, ICON plc, IQVIA, Syneos Health, Takeda
  • HighTech IT & Internet: Amazon, Microsoft, Google
  • Academia: Weizmann Institute, Harvard Medical School
  • Others in 2022: Self employed, Home, Freelance

Marquee Corporations:

Their Leaders are 1st Degree Connections of LPBI Group’s Founder 


Corporate Leaders are 1st Degree Connections of LPBI Group’s Founder 

  • 30% of the Total of 7,485 1st Degree Connections are +1,000 Directors, +700 CEOs, +400 VPs
  • +200 positions are of the company Presidents (2.25%)
Position of Interest Frequency Summary (include overlaps)
Position Name  














Industry Focus of the Marquee Corporations who’s Leaders are

1st Degree Connections to LPBI Group’s Founder

Summary of 3 Most Common Positions in Companies with 9 or More Connections



Number of contacts



1st position count



2nd position count



3rd position count
Novartis 16 Manager 3 Lead 3 Director 2
Teva Pharmaceuticals 16 Senior Director 3 R&D Director & Manager 3 Senior Managers (other) 2
Amazon 15 Senior Program Manager 2 associate 2 Marketing & Sales Leader 2
AstraZeneca 14 Senior Director 2 Talent acquisition 2 Vice President 2
Johnson & Johnson 13 Vice President 3 Scientist 3 Director 3
Weizmann Institute of Science 13 Head, Leader, & Director 4 Scientist 3 Researcher 2
Philips 12 Head 2 Leader 2 Architect & Engineer 2
ICON plc   11 Recruiter & Recruitment Consultant 4 Directors 2 Manager of Clinical Operations 2
IQVIA 11 Director 3 Specialist 2 Consultant 2
Syneos Health 11 Director 3 Oncology Sales Representative 2 Clinical Research 2
Harvard Medical School 10 Professor 3 Instructor 2 Fellow 2
Mircrosoft 10 Engineer & Architect 3 Manager 2 Recruiter 2
Takeda 10 Head & Lead 4 Manager 3 Associate Director 2
Google 9 Manager 3 Engineer 2 Scientist & Researcher 2
Self-Employed 127 Consultant 24 Writer & Editor 10 Manager & Managing Director 8
Freelance 24 Consultant 7 Writer & Editor 6 Programmer 2


In Highest Frequency of Leading Positions we find the C-Suite

Of Note: Seniority of the Connections’ Positions – Managers, Directors, CEOs, Founders, Vice Presidents

Of Note: Managers, Directors, CEOs, Founders and VPs


Of Note: Managers, Directors, CEOs, Founders and VPs: Ease of Approachability in decrease order: Most accessible are Director level followed by VP level and least approachable are the CEOs in the corner offices.

Of Note: CFOs, Coordinators, Chairman/Vice Chairman, Experts, Business Owners, Researchers, Medical, Editors, others.


The Data was extracted on 2/13/2022 from LinkedIn Cloud.


First Degree LinkedIn Connections of

                       Aviva Lev-Ari, PhD, RN                                  

Frequency Summary

The Positions of All Connections                        Frequency Summary                                                (overlaps counted once)
Positions Frequency



Manager (other) 787
Director 733
CEO 718
Founder 449
ZZ_ other statistically insignificant positions 433
Vice President 360
Consultant 298
President 196
Specialist 160
Professor 148
Scientist 144
recruiter 138
Advisor 131
Business/Organization Owner 123
Co-Founder 120
Head 116
Managing Director 104
Engineer 86
Analyst 85
Managing Partner 76
Partner (other) 71
Principal 68
Retired 67
Writer 64
(Board) Member 62
Admin 53
Talent Acquisition 52
Account Manager 51
Officer 51
Chief Financial Officer 48
Coordinator 47
(Vice) Chairman 47
Associate 46
Assistant 45
Leader 42
Coach 39
Researcher 39
Account Executive 35
Expert 33
Business Development 33
Senior position (other) 33
Research Related (other) 30
Executive (other) 30
Strategy related (other) 28
Medical (other) 27
Attorney 26
Representative 26
Accounting (other) 24
Developer 24
Editor 24
Designer 23
Faculty 22
Supervisor 22
Principal Consultant 22
Lecturer 22
Agent 22
Intern 22
Sales Related (other) 22
Architect 20
Strategist (other) 19
Chief Operating Officer 19
Teacher 17
Technician 17
Actor 16
Instructor 15
Student 15
Nurse 15
Chemist 14
Mentor 14
Author 14
Investigator 13
Marketing (other) 13
Sales Executive 12
Chief Scientific Officer 11
Broker 11
Cardiologist 11
Chief (other) 11
Venture Partner 10
Postdoctoral Fellow 10

Read Full Post »

The 40th Anniversary of SRI ORGANON TOASTMASTERS virtual celebration on Tuesday, August 18, 11:45 a.m.-1:00 p.m

Reporter: Aviva Lev-Ari, PhD, RN



Past Member of SRI Organon Toastmasters, 5/1985 – 9/1988: Aviva Lev-Ari, PhD, RN


I was a Competent Toastmasters working on the Distinguished Toastmasters rank.

Today, 8/7/2020 was invited to attend the SRI Organon Toastmasters 40th Anniversary. 

The picture on my Student ID Card at University of California, Berkeley, 9/1978 – 12/1983


From: NAOMI LEVENSON <na8mi@comcast.net>

Date: Friday, August 7, 2020 at 3:38 PM

Subject: SRI Organon Anniversary

SRI Organon Toastmasters turned 40 in February!

We invite you to join the virtual celebration on Tuesday, August 18, 11:45 a.m.-1:00 p.m.



More information is on the attached flyer.

Plan to come to the meeting early and stay afterwards. There will be time to reminisce and catch up.

Do you have any memories you might want to share. You can add your thoughts, anecdotes and comments on   https://tinyurl.com/yxl4nuu4.

Bring your own beverage for the TOAST!

Please plan to attend.

Naomi Levenson


40th Anniversary Flyer (1)

Read Full Post »

LPBI Group’s Founder – A Profile for a Wikipedia Entry

Curator: Zach Day, with editorial comments by Prof. Marcus W. Feldman, Dr. Joel T. Shertok, PhD and Gail S. Thornton, PhD(c), MA

Updated on 5/24/2022


Aviva Lev-Ari, Ph.D., R.N.



Aviva Lev-Ari, Ph.D., R.N., is the founder of Leaders in Pharmaceutical Business Intelligence Group (LPBI Group), a Newton, Massachusetts, start-up company launched in 2012 in the domain of Pharmaceutical Media.

The LPBI Group incorporates into three interrelated domains:

  • an open-access online scientific journal,
  • a series of 16 BioMed e-books covering five specialties of Medicine and Life Sciences (Cardiovascular, Genomic Medicine, Cancer, Immunology and Precision Medicine) and
  • real-time press coverage of BioMed scientific and medical conferences.

Year over year, LPBI Group continues to increase its readership of medically valuable content, which includes more than 5,800 scientific articles with over 1.8 million views in its online scientific journal. The LPBI Group goal is to make scientific content universally accessible to the pharmaceutical media and electronic scientific publishing communities.

https://pharmaceuticalintelligence.com/ at @pharma_BI and @AVIVA1950. Additionally, the 16 BioMed e-books can be accessed on the website: https://pharmaceuticalintelligence.com/biomed-e-books/ and on https://lnkd.in/ekWGNqA

Please visit the LPBI Group Wikipedia page to learn more about our company. [ZACH: CAN YOU PUT A LINK TO THE LPBI GROUP Wikipedia Page here?] 

Ongoing Commitment to Life Sciences

The LPBI Group team curates life sciences and medical literature producing clinical interpretations of scientific findings and publishing the results as articles in LPBI Group’s open-access online scientific Journal http://pharmaceuticalintelligence.com.

Dr. Lev-Ari serves as Editor-in-Chief of the Journal and of the series of 16 BioMed e-books. The e-Books cover five cardinal Medical specialties https://lnkd.in/ekWGNqA. The books serve physicians in the community, allied healthcare professionals, medical students and an extensive global community of e-readers in life sciences and biomedicine. The books are also included in the medical curricula of several prominent medical schools in the United States.

The LPBI Group has competencies in real-time coverage of Medical and Biotech global conferences, using methodology developed by Dr. Lev-Ari. This method allows for the generation of e-Proceedings with a single click. Dr. Lev-Ari developed a series of templates used during the Conferences to generate Tweets representing quotes by speakers and their affiliations. To date Dr. Lev-Ari has generated 60 e-Proceedings and 36 Tweet Collections. Part Three: Conference eProceedings DELIVERABLES & Social Media Analytics


Early Life and Education

Dr. Aviva Lev-Ari was born in Bucharest, Romania, to a Jewish family with a 400-year history in Europe. Along with her father and older sister, Pnina Abir-Am, Ph.D. [Brandeis University], the family moved to Israel in December 1958. [Her mother succumbed to breast cancer in September 1956 when Aviva was 6 years old].  As a young girl in a 10-year-old State of Israel, the new reality was significantly different than that of her European early years. She loved oranges and bananas both of which were rare in Eastern Europe in the 50s. She bonded with the nature and the geography of Israel, the wild flowers of the hilly slopes of Mount Carmel and the wide panoramic view of the Western bound of the Valley of Jezreel from the window of her bedroom shared with her sister. Dr. Lev-Ari graduated with honors from the prestigious private institution, Huggim High School on Mount Carmel, in Haifa in 1968. This gymnasium was established in 1932 by German Jewish emigres, who were former German University Professors, forced to leave their Academic positions by the Nazis.

These high school years made a long lasting impression on Aviva, a studious, achievement–oriented, hardworking student who was motivated to excel in her studies.

Following her IDF military service, she studied at the Hebrew University (HUJI) in Jerusalem for six years, where she earned her B.A. and M.A. degrees (Cum Laude) in Urban Planning and Economic Geography in 1976. At HUJI she became a very scholarly-inclined student, motivated by the outstanding faculty members, i.e., Prof. S. Reichman and Prof. Louis Guttman.

Her Masters thesis applied Facet Theory, SSA, MSA & POSAC, the novel non-parametric paradigm in Statistics developed by Prof. Louis Guttman in 1946 and during the 60s and the 70s, while using the latest version of the computer programs that were included for the 1st year in SPSS in 1976. The thesis was filed with the Graduate Division in July 1976, conferring and confirming the highest GPA recorded at the registrar of the Faculty of Social Sciences at HUJI to-date (95/100).

She then worked at the Technion, which was known to hire chiefly its own graduates, in Applied Research as the first HUJI graduate to be hired. During 1977-1978 at the Technion, she applied Facet Theory in Urban Planning. She came to the United States to pursue her doctoral studies in September 1978. Her postgraduate studies were at the University of California – Berkeley, where she earned her doctorate in 1983 in Industrial Organization Economics and Location Theory under Prof. Allan Pred, a famous AAAG Fellow +40 years of the 20th century on the Faculty at Berkeley, the #2 Department of Geography in the country. The Berkeley academic environment was most conducive for interdisciplinary research and for expression of the highest level of creativity; both were Prof. Allan Pred’s contributions as mentor and as advisor to Aviva. The intellectual stimulation culminated in her Ph.D. thesis, and other milestones beyond the years at Berkeley. Prof. Pred presented a draft of her dissertation at MIT in October 1983. Recollections of Years at UC, Berkeley, Part 1 and Part 2:

  • Recollections: Part 1– My days at Berkeley, 9/1978 – 12/1983 – About my doctoral advisor, Prof. Allan Pred, other professors and other peers


  • Recollections: Part 2– “While Rolling” is preceded by “While Enrolling” Autobiographical Alumna Recollections of Berkeley – Aviva Lev-Ari, PhD’83



Additionally, Dr. Lev-Ari was Prof. Louis Guttman’s student in 1975-76. She was known for applying his methods in the top-tier consulting industry in the United States using the software licensed via Yissum (Technology Transfer Office of HUJI) at SRI International for Fortune 50 companies e.g., GM, Alcan, Rhone Poulenc. At the University of California – Berkeley, she taught upper division courses in Quantitative Methods using SSA, MSA & POSAC in 1979, 1980, 1981. In 1990-91, she was the developer of the models that made a cardinal organizational change from managerial to brokerage agencies by a top financial & insurance firm based in Boston, Massachusetts, where she spent the fall and winter of 1990/91 on the 52nd floor of one of the two tallest skyscrapers in Boston.

While in California, she also studied Organizational Behavior under James G. March and Harold J. Leavitt at Stanford University Graduate School of Business, in an Exchange Program between Berkeley and Stanford in 1980-81.

Autobiographical Annotations: Tribute to My Professors


Dr. Lev-Ari worked in the domains of her expertise for 25 years, at several of the most esteemed institutions in the United States, among them, SRI International – Menlo Park, California; MITRE – Bedford, Massachusetts; PSC – Cambridge, Massachusetts (HQS: Dallas, TX); and McGraw Hill – Monterey, California (HQS: NY, NY).

Dr. Lev-Ari reinvented her career toward a new direction in Health Care, by being admitted into the Bouve College of Health Sciences in 2005, and earning a nursing degree at Northeastern University (Nurse Practitioner Direct Entry track – 800 candidates for 26 places.) For comparison, at the Ph.D. Program Admission, there were 240 candidates for 12 places and only 8 earned the degree five years later.

At Northeastern University she researched cardiovascular pharmacotherapy with her professor of Pharmacology for four independent research courses during 2006-2007. Pharmacology was the domain she liked the most at Bouve College. She developed the concept of a combination drug therapy (three agents) for prevention of macro cardiovascular events. She already knew then, that she would return to pharmaceutical study some day.


Reflections on a Four-phase Career

Dr. Lev-Ari’s career, as presented in Reflections on a Four-phase Career: Aviva Lev-Ari, PhD, RN, March 2018, has the following phases:

  • Phase 1: Research, 1973 – 1983
  • Phase 2: Corporate Applied Research in the US, 1985 – 2005
  • Phase 3: Career Reinvention in Health Care, 2005 – 2012
  • Phase 4: Electronic Scientific Publishing, 4/2012 to present


This article was written in March 2018. It was prepared for publication in American Friends of the Hebrew University (AFHU), May 2018 Newsletter, Hebrew University’s HUJI Alumni Spotlight Section.

Aviva Lev-Ari’s profile was up on 5/3/2018 on AFHU website under the Alumni Spotlight at https://www.afhu.org/


Early Career

Dr. Lev-Ari started her career conducting research from 1973 -1983.  She then transitioned into Corporate Applied Research in the United States between 1985-2005.

Second Career

Dr. Lev-Ari reinvented her career in the Health Care arena, and earned her R.N. degree. She worked in Clinical Nursing Management, 2008–2012, in post-acute settings and was Supervisor of a Long-Term Acute Care Hospital (LTACH) in Waltham, Massachusetts.

Recent Career

Dr. Lev-Ari’s most recent transition has been into Electronic Scientific Publishing, from April 2012 to the Present. Currently she is the Director & Founder of the Leaders in Pharmaceutical Business Intelligence (LPBI) Group. She is the developer of several curation methodologies for scientific content, and developed a unique methodology for the creation of an electronic Table of Contents (eTOCs). She was initiated into the development of workflow procedures involved in the systematic population of all eTOCs by Expert Editors, that culled articles from the journals’ research categories to create a one of a kind eTOCs for each volume [except for Cancer Volume 1].

In 2012, Dr. Lev-Ari launched, and currently leads the Journal, PharmaceuticalIntelligence.com. She is the Editor in Chief of the Journal and of the BioMed e-Series. The transformative work done at LPBI Group allows cutting-edge biomedical research innovation to be widely disseminated and accessible to the research and the non-research communities. Her method of curation represents a mode of scientific communication including synthesis, analysis, and interpretation.

Experts, authors, and writers add their knowledge and expertise in re-thinking and conceptualizing subjects selected in their domain of expertise, to form new curations or updating existing ones. The books are transformative in their capacity to accelerate diffusion of scientific innovations. To date 115,000 pages have been downloaded form the 16 Volumes.

The curation is done by experts with a perspective within each field, allowing for the creation of scientific content that combines conceptual evolution within the scientific breakthroughs analyzed with their anticipated future implications.

Dr. Lev-Ari’s work is innovative and creative. She has perfected the art of scientific curation for medical evaluation of cutting-edge literature. It is available through LPBI Group’s open access Journal. Dr. Lev-Ari has tutored numerous students and young adults in her career. LPBi is enjoying an excellent reputation within the field, for the valuable information it provides. Dr. Stephen Williams, a Professor of Pharmacology at the Sbarro Health Research Organization at Temple University said of Dr. Lev-Ari,

“I have never met anyone so driven as Dr. Lev-Ari. She had a great vision and knows how to put that vision into practice. She has an impressive amount and quality of people she has direct contact with.” Regarding Dr. Lev-Ari’s accomplishments and personal character, he noted: “She has more energy than some 20 and 30-somethings. She does not stop until she sees her vision realized.”

Personal Life

Dr. Lev-Ari married in 1971 a newly minted graduate of the Technion and Officer in the Signal Corps of IDF. Hanoch Lev-Ari, Ph.D., Fellow IEEE, has been a Professor of EE at Northeastern University since 1990. He is a graduate of Stanford University, Ph.D. ’84 in EE, and the Technion, BSEE ’71 & MSEE ’76. They lived in Palo Alto, California from 1978-1990 and in Newton Center, Massachusetts since September 1990. They have one married son, Edan, a 2007 Cornell University graduate working at Natick Lab, Natick, MA

Dr. Lev-Ari enjoys swimming, classical music, Jazz, non-fiction literature, fashion design, fashion photography, orchids and peonies.




Dr. Lev-Ari’s expertise is in Cardiovascular Diseases